Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4124 | UCPVax + Nivolumab Wiki | 0.58 |
| drug319 | Antibody titration Wiki | 0.58 |
| drug4745 | standard chemotherapy Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung NIH | 0.26 |
| D008175 | Lung Neoplasms NIH | 0.17 |
| D016638 | Critical Illness NIH | 0.07 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.05 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.05 |
| D055371 | Acute Lung Injury NIH | 0.05 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.04 |
| D007239 | Infection NIH | 0.03 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0030358 | Non-small cell lung carcinoma HPO | 0.26 |
| HP:0100526 | Neoplasm of the lung HPO | 0.17 |
Navigate: Correlations HPO
There are 3 clinical trials
The aim of the present study is to evaluate the effects of Lactobacillus coryniformis K8 consumption on the incidence and severity of Covid-19 in health workers exposed to the virus. This is a preventive study
Description: The incidence of SARS CoV-2 infection will be confirmed by PCR or antigen test
Measure: Incidence of SARS CoV-2 infection in healthcare workers Time: 8 weeksDescription: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will required hospital admission because of Covid-19
Measure: Incidence of hospital admissions caused by SARS-CoV-2 infection Time: 8 weeksDescription: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will required ICU admission because of Covid-19
Measure: Incidence of ICU admissions caused by SARS-CoV-2 infection Time: 8 weeksDescription: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will develop pneumonia because of Covid-19
Measure: Incidence of pneumonia caused by SARS-CoV-2 infection Time: 8 weeksDescription: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will require oxygen support because of Covid-19
Measure: Incidence of oxygen support requirement caused by SARS-CoV-2 infection Time: 8 weeksDescription: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will develop gastrointestinal symptoms because of Covid-19
Measure: Incidence of gastrointestinal symptoms caused by SARS-CoV-2 infection Time: 8 weeksDescription: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with body's temperature > 37.5 ºC during the course of the disease
Measure: Days with body's temperature > 37.5 ºC Time: 8 weeksDescription: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with cough during the course of the disease
Measure: Days with cough Time: 8 weeksDescription: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with fatigue during the course of the disease
Measure: Days with fatigue Time: 8 weeksDescription: Use of drugs (dosis and duration of the treatment) for Covid-19 treatment
Measure: Medical treatment Time: 8 weeksA prospective case-control pilot study to evaluate the possible effect of a probiotic mixture in the improvement of symptoms, the reduction in the number of days of hospitalization and the increase in the percentage of patients with negative PCR after infection with the coronavirus SARS-CoV-2.
Description: Percentage of patients with discharge to ICU.
Measure: Cases with discharge to ICU. Time: 30-daysDescription: Percentage of patients with home discharge.
Measure: Patients with home discharge. Time: 30-daysDescription: Percentage of deaths.
Measure: Mortality. Time: 30-daysDescription: Number of adverse events that occur during the treatment period, attributable or not to the intervention product.
Measure: Treatment safety assessed by number of adverse events. Time: 30-daysDescription: Number of new cases of positive SARS-Cov-2 infection by PCR analysis.
Measure: New cases of SARS-Cov-2 infection among healthcare personnel caring for the patients. Time: 30-daysDescription: Percentage of patients with negative PCR for SARS-CoV-2.
Measure: Patients with negative PCR result for SARS-CoV-2 infection. Time: 30-daysWhen the COVID-19 virus infects a person, it enters the lung epithelial cells of its host and uses its genetic material to replicate. The pulmonary epithelial cells of a part of the population, known as "secretors", are capable of expressing the antigens of the "ABO" system on their surface. This secretory status can be established by determining the antigens of the Lewis blood group system. When the virus replicates in an "secreting" individual, the antigens of the "ABO" system of the infected individual will be present on the surface of the viruses formed in his/her lungs. It was shown in 2003 that the response of a given individual to the transmission of a virus depends on his/her blood group and on the antigens of the "ABO" system carried by the virus. A patient of group "O" would thus defend himself much better against a virus carrying antigens of blood group "A", the natural antibodies "anti-A" of the patient reducing the ability of the virus to bind to its specific receptor on pulmonary epithelial cells, to penetrate them to replicate itself. The first data collected in Wuhan (China) seems to confirm this hypothesis. A COVID-19 virus transmission model can therefore be established on the basis of blood groups. In order to reduce the spread of the virus among nursing staff, it is possible to establish a preferential algorithm for patient management based on the "ABO" and "Lewis" blood groups of patients and "ABO" of nursing staff in health care units, if operational and human conditions allow.
Description: Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-A antibody concentration Time: baselineDescription: Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-A antibody concentration Time: Day 4Description: Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-A antibody concentration Time: Week 1Description: Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-A antibody concentration Time: Week 2Description: Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-A antibody concentration Time: Week 3Description: Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-B antibody concentration Time: baselineDescription: Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-B antibody concentration Time: Day 4Description: Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-B antibody concentration Time: Week 1Description: Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-B antibody concentration Time: Week 2Description: Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Measure: Anti-B antibody concentration Time: Week 3Description: Blood group (ABO/LE)
Measure: Blood group Time: baselineAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports